Advertisement
Wednesday 29 November 2016: Poster Sessions: Molecular targeted agents I: Poster (Board P046)| Volume 69, SUPPLEMENT 1, S32, December 2016

TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants

DOI:https://doi.org/10.1016/S0959-8049(16)32675-2
TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants
Previous ArticleKIF5B-RET fusion gene may involve in EMT via the regulation of transcription factor, FOXA2
Next ArticleRole of CCL20 in NF-κB mediated TRAIL resistance of pancreatic cancer cell lines
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0959-8049(16)32675-2

      Copyright

      © 2016 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX